Ashleigh Parkin


Ashleigh completed a Bachelor of Advanced Science (with Honours), majoring in genetics, molecular biology, microbiology and pathology at University of New South Wales, Sydney in 2015. In 2016 she began her PhD studies at the Garvan Institute under the supervision of Marina Pajic and Associate Professor Paul Timpson. Her work is focused on developing novel personalised medicine strategies for pancreatic cancer and investigating the mechanisms behind their therapeutic efficacy using complex in vitro and in vivo models. Ashleigh was awarded an Australian Post Graduate Award, a Sydney Catalyst Top Up Research Scholar Award, as well as a Sydney Catalyst Travel and Education Award to support her PhD studies. 

Ashielgh is passionate about translational research and is focused on identifying and validating novel molecular targets and therapeutic strategies in order to help improve outcomes for patients suffering with pancreatic cancer. Ashleigh's other passions include tennis, interior design and her two cocker spaniels.



  • Personalised Medicine
  • Signalling Pathways
  • Molecular and Cellular Biology
  • Therapeutic Resistance
  • Experimental Cancer Models 


Dual inhibition of JAK and Src: A novel and promising therapeutic combination for pancreatic cancer

Pancreatic cancer (PC) has a 5-year survival of only 6%, and persists as the 4th most common cause of cancer-related death in Western societies. A more tailored treatment approach may be beneficial as the current standard-of-care therapies offer only a modest increase in overall patient survival. Recent large-scale genomic studies have revealed that the Src/JAK/STAT3 signalling pathway is deregulated in up to 35% of PC, and is yet to be systematically examined in this disease. Consequently, we hypothesized that targeting pancreatic tumours with activated JAK/STAT3 signalling with selective JAK1/JAK2 or JAK3 inhibitors and an Src inhibitor represents a promising novel therapeutic strategy for this disease.

Click to view full size image